Concord Biotech Ltd.
NSE: CONCORDBIOConcord Biotech Ltd.: A 30-second snapshot
Concord Biotech trades at Rs 1,330, up 12.93% over the past 3 months but still 27.83% below year-ago levels and 29.32% off its 52-week high, currently sitting above both its 50-DMA (Rs 1,262.9) and 200-DMA (Rs 1,256.62) with RSI at 58.74 (neutral). Trailing PE of 57.43x (forward 34.61x) ranks 4th of 6 among Pharma sector peers on PE, ROE and quality score, with a quality score of 30 and ROE of 13.54%. 5-year revenue and earnings growth of -24.1% and -37% respectively contrast with recent Q1 FY27 headlines describing 'strong revenue and profit growth.'
P/E
57.4
Forward P/E
34.6
ROE
+13.5%
Debt / Equity
0.12
Profit Margin
+24.7%
Div. Yield
+0.6%
5Y ROE > 15%
3/5
5Y FCF > 0
4/5
Quality
52/100
News
6 headlines · 1 positive · 0 negative
Concord Biotech Ltd June-Quarter Consol Net Profit 585.3 Million Rupees - TradingView
TradingView
CONCORDBIO: Strong revenue and profit growth in Q1 FY27, with a notable non-recurring labour code impact - TradingView
TradingView
Concord Biotech (CONCORDBIO) Q3 24/25 earnings summary - Quartr
Quartr
Concord Biotech (CONCORDBIO) Q4 24/25 earnings summary - Quartr
Quartr
Price to sales forward of Concord Biotech Ltd. – NSE:CONCORDBIO - TradingView
TradingView
Recent context
- ·Headlines from July 31 (TradingView) describe 'strong revenue and profit growth' for Q1 FY27, including a reported consolidated net profit of Rs 585.3 million for the June quarter, alongside a mention of a non-recurring labour code impact.
- ·News sentiment across the 6 most recent items is neutral overall (1 positive, 5 neutral, 0 negative), with no negative coverage in the sample.
- ·Price has recovered 12.93% over the past 3 months, moving back above both the 50-DMA and 200-DMA after a 1-year decline of 27.83%.
Strengths
- +Debt-to-equity of 0.115 with a falling debt trend, among the lowest leverage levels in the available Pharma peer set.
- +Free cash flow was positive in 4 of the measured years, with a consistency score of 59.
- +Trading above both the 50-DMA (Rs 1,262.9) and 200-DMA (Rs 1,256.62) following a 12.93% price rally over the past 3 months.
- +Profit margin of 24.73% alongside a dividend yield of 0.57%.
Weaknesses
- −5-year revenue growth of -24.1% and earnings growth of -37% indicate sustained top-line and bottom-line contraction over the measurement period.
- −Trailing PE of 57.43x sits above peers Cipla (35.37x), Sun Pharma (41.62x) and Dr. Reddy's (28.90x), while the forward PE of 34.61x implies an earnings recovery not yet reflected in trailing figures.
- −Still down 27.83% over the past 1 year and 29.32% below its 52-week high, despite the recent 3-month price recovery.
- −Quality score of 30 and ROE of 13.54% both rank 4th of 6 sector peers, trailing Apollo Hospitals (21.5% ROE) and Sun Pharma (14.72% ROE).
Open questions
- ?Does the 5-year revenue and earnings decline reflect a structural shift in the business, or is it tied to specific one-off items such as the 'non-recurring labour code impact' referenced in recent headlines?
- ?How does the Q1 FY27 growth described in recent news headlines reconcile with the 5-year trailing decline in revenue and earnings?
- ?What assumptions underlie the gap between the trailing PE (57.43x) and forward PE (34.61x)?
- ?How does the company's low leverage (D/E 0.115) and 4-year FCF-positive track record weigh against its mid-pack quality score (30, ranked 4th of 6) among sector peers?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| CONCORDBIO | Concord Biotech Ltd.You're viewing | 57.4 | +13.5% | 30 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹1,330.00
SMA 50
₹1,262.90
SMA 200
₹1,256.62
RSI (14)
58.7 (neutral)
From 52w high
-29.3%
1Y return
-27.8%
3M return
+12.9%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- high5-year revenue growth of -24.1% and 5-year earnings growth of -37% indicate sustained top-line and bottom-line contraction over the measurement period, with earnings declining faster than revenue.
- mediumTrailing PE of 57.43x sits above pharma peers Cipla (35.37x), Sun Pharma (41.62x) and Dr. Reddy's (28.90x) despite a 5-year earnings decline of -37%. The forward PE of 34.61x implies an earnings recovery not yet reflected in trailing results.
- mediumStock is still down 27.83% over the past 1 year and 29.32% below its 52-week high, even though it has rallied 12.93% over the past 3 months and now trades above both its 50-DMA (Rs 1,262.9) and 200-DMA (Rs 1,256.62), with RSI at 58.74 (neutral).
- lowQuality score of 30 and ROE of 13.54% both rank 4th of 6 sector peers, below Apollo Hospitals (21.5% ROE, quality score 44) and Sun Pharma (14.72% ROE, quality score 56). Peer priceChange1Y is null for all 5 comparators, limiting relative price-performance benchmarking, and analyst consensus (2.2) is based on a small sample of 5 analysts.
Cross-section contradictions
- 5-year revenue growth of -24.1% and earnings growth of -37% contrast with recent news headlines describing 'strong revenue and profit growth in Q1 FY27' and a 3-month price gain of 12.93% -- the long-run contraction metric and the most recent reported quarter point in different directions.
- FCF was positive in 4 of the measured years with a falling debt trend (D/E 0.115), even as 5-year revenue and earnings growth are both negative -- cash generation and reported multi-year earnings trends diverge over the period.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days